Summary
No claims can be verified against the provided FDA-approved prescribing information because the relevant label section text is not provided; all extracted claims are marked 'absent from the label' under the supplied label-support metadata.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx is a biologic medication used to treat autoimmune diseases including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Cosentyx works by blocking the action of interleukin-17A (IL-17A).
Label support marked absent; INDICATIONS AND USAGE section text not provided.
By inhibiting IL-17A, Cosentyx reduces inflammation.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Cosentyx may suppress the immune system.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
A waiting period is necessary after Cosentyx treatment to ensure the immune system has recovered.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
If live vaccines are administered too soon after Cosentyx treatment, the immune system may not be able to mount an adequate response.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Administering live vaccines too soon after Cosentyx treatment may lead to reduced vaccine efficacy.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Administering live vaccines too soon after Cosentyx treatment may lead to adverse reactions.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
A general guideline is to wait at least 4 to 6 weeks after the last dose of Cosentyx before receiving a live vaccine.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
MMR vaccine is recommended to be given 4 to 6 weeks after the last dose of Cosentyx.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Varicella vaccine is recommended to be given 4 to 6 weeks after the last dose of Cosentyx.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Oral poliovirus vaccine is recommended to be given 4 to 6 weeks after the last dose of Cosentyx.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Receiving a live vaccine too soon after Cosentyx treatment may result in increased risk of vaccine-related side effects.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Receiving a live vaccine too soon after Cosentyx treatment may result in potential vaccine-related complications.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Cosentyx treatment can suppress the immune system, making it more challenging for the body to respond to live vaccines.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
It is not recommended to get a live vaccine while taking Cosentyx.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Inactivated vaccines do not require a waiting period after Cosentyx treatment.
Label support marked absent; INDICATIONS AND USAGE section text not provided.
Contradictions
Important Omissions
FDA-label content for relevant sections (e.g., vaccination/live vaccine guidance, immunogenicity/warnings, administration instructions) is not provided in the prompt; therefore required label-specific details cannot be checked.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Multiple time-specific and outcome-specific vaccination guidance claims (including a 4–6 week waiting period and effects on efficacy/adverse reactions) cannot be verified against the provided prescribing information content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All extracted claims are unverified/flagged as absent from the label due to missing label section text.
Suggested Improvement
Provide the actual FDA-approved label text for the sections addressing indications and vaccination/live vaccine guidance (not just the section heading), then re-evaluate claims against that text.